By increasing the in vitro E:T ratio we could eventually eradicate TP53-deficient AML cells and observed similar exhaustion and differentiation profiles as in CAR T-cells engaging isogenic, TP53-proficient AML cells at lower E:T ratios. The gene discussed is TP53; the disease is acute myeloid leukemia.